


FEE TRANSMITTAL
for FY 2003
(Large Entity)



Complete if Known	
Application Number	10/019,661
Filing Date	April 29, 2002
First Named Inventor	Lian-Hui ZHANG et al.
Group Art Unit	1638
Examiner Name	Anne R. Kubelik
Attorney Docket Number	2977-127
Customer No.	6449
Total Amount of Payment	(\$ 420.00)
Confirmation No.	5708

1638
\$
TRW

METHOD OF PAYMENT (check one)

1. ☒ The Commissioner is hereby authorized to charge additional fees and credit any overpayment to Deposit Account Number 02-2135 in the name of Rothwell, Figg, Ernst & Manbeck
- ☒ Charge any Additional Fee Required Under 37 CFR 1.16 and 1.17
- ☐ Applicant claims small entity status
2. ☐ Payment Enclosed
- ☐ Check
- ☐ Credit Card

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Fee Code	Fee Paid	Fee Description	Fee Paid
1051	130	Surcharge - late filing fee or oath	[]
1052	50	Surcharge - late provisional filing fee or cover sheet	[]
1053	130	Non-English specification	[]
1812	2,520	For filing a request for reexamination	[]
1804	920	Requesting publication of SIR prior to Examiner action	[]
1804	1,840*	Requesting publication of SIR after Examiner action	[]
1251	110	Extension for reply within first month	[]
1252	420	Extension for reply within second month	[\$420]
1253	950	Extension for reply within third month	[]
1254	1,480	Extension for reply within fourth month	[]
1255	2,010	Extension for reply within fifth month	[]
1401	330	Notice of Appeal	[]
1402	330	Filing a brief in support of an appeal	[]
1403	290	Request for Oral Hearing	[]
1451	1,510	Petition to institute a public use proceeding	[]
1452	110	Petition to revive -unavoidable	[]
1453	1,330	Petition to revive - unintentional	[]
1501	1,330	Utility issue fee (or reissue)	[]
1502	480	Design issue fee	[]
1503	640	Plant issue fee	[]
1460	130	Petitions to the Commissioner	[]
1807	50	Processing fee under 37 CFR 1.17(q)	[]
1806	180	Submission of Information Disclosure Statement	[]
8021	40	Recording each patent assignment per property (times number of properties)	[]
1809	770	Filing a submission after final rejection (37 CFR .129(a))	[]
1810	770	For each additional invention to be examined (37 CFR 1.129(b))	[]
1801	770	Request for Continued Examination (RCE)	[]
1802	900	Request for expedited examination of a design application	[]
1504	300	Publication fee for early, voluntary, or normal publication	[]
1505	300	Publication fee for republication	[]
1455	200	Filing application for patent term adjustment	[]
1456	400	Request for reinstatement of term reduced	[]
		Other fee (specify)	[]

FEE CALCULATION

1. FILING FEE

Fee Code	Fee \$	Fee Description	Fee Paid
1001	770	Utility filing fee	[]
1002	340	Design Filing Fee	[]
1003	530	Plant Filing Fee	[]
1004	770	Reissue Filing Fee	[]
1005	160	Provisional Filing Fee	[]

SUBTOTAL \$

2. CLAIMS


Total Claims Independent	Extra Claims	Fee	Fee Paid
[] - 20** = [] x		\$18 = []	
Claims [] - 3** = [] x		86 = []	
Multiple Dependent Claims +		290 = []	

**or number previously paid, if greater;

SUBTOTAL \$

* Reduced by Basic Filing Fee Paid **SUBTOTAL \$420.00**

SUBMITTED BY		Complete (if applicable)			
NAME AND REG. NUMBER	Leigh Z. Callander, Reg. No. 55,035				
SIGNATURE	DATE	DEP ACCT USER ID			
<i>Leigh Z Callander</i>	July 12, 2004		02-2135		


**IN THE
UNITED STATES
PATENT AND TRADEMARK OFFICE**

<i>Application No.</i>	10/019,661
<i>Filing Date</i>	April 29, 2002
<i>First Named Inventor</i>	Lian-Hui ZHANG et al.
<i>Group Art Unit</i>	1638
<i>Examiner Name</i>	Anne R. Kubelik
<i>Confirmation No.</i>	5708
<i>Attorney Docket No.</i>	2977-127

Title of the Invention: GLOBAL REGULATORS OF BACTERIAL PATHOGENIC GENES AS TARGETS FOR ENGINEERING DISEASE RESISTANCE

**PRELIMINARY AMENDMENT AND
RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner of Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Prior to consideration on the merits of the above-referenced application, please consider the following amendments and remarks.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 8 of this paper.